The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have jointly identified ten principles of good practice for artificial intelligence (AI) in the drug lifecycle.[1] These principles guide the use of AI in evidence generation and monitoring throughout all phases of medicine, from early research and clinical trials to manufacturing and safety monitoring.[1] This is the first step of the renewed cooperation between the EU and the USA in the field of new medical technologies.[1] The principles were established as part of the work of the EMA and the FDA to promote the safe and ethical use of AI.[1][2]